Protein Kinases as Drug Development Targets for Heart Disease Therapy
AbstractProtein kinases are intimately integrated in different signal transduction pathways for the regulation of cardiac function in both health and disease. Protein kinase A (PKA), Ca2+-calmodulin-dependent protein kinase (CaMK), protein kinase C (PKC), phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) are not only involved in the control of subcellular activities for maintaining cardiac function, but also participate in the development of cardiac dysfunction in cardiac hypertrophy, diabetic cardiomyopathy, myocardial infarction, and heart failure. Although all these kinases serve as signal transducing proteins by phosphorylating different sites in cardiomyocytes, some of their effects are cardioprotective whereas others are detrimental. Such opposing effects of each signal transduction pathway seem to depend upon the duration and intensity of stimulus as well as the type of kinase isoform for each kinase. In view of the fact that most of these kinases are activated in heart disease and their inhibition has been shown to improve cardiac function, it is suggested that these kinases form excellent targets for drug development for therapy of heart disease. View Full-Text
Share & Cite This Article
Dhalla, N.S.; Müller, A.L. Protein Kinases as Drug Development Targets for Heart Disease Therapy. Pharmaceuticals 2010, 3, 2111-2145.
Dhalla NS, Müller AL. Protein Kinases as Drug Development Targets for Heart Disease Therapy. Pharmaceuticals. 2010; 3(7):2111-2145.Chicago/Turabian Style
Dhalla, Naranjan S.; Müller, Alison L. 2010. "Protein Kinases as Drug Development Targets for Heart Disease Therapy." Pharmaceuticals 3, no. 7: 2111-2145.